Loading...
•
Sep 30, 2024
Akero Q3 2024 Earnings Report
Akero Therapeutics reported financial results for the third quarter of 2024 and provided business updates.
Key Takeaways
Akero Therapeutics reported cash, cash equivalents and short and long-term marketable securities of $787.1 million as of September 30, 2024. The first patient was dosed in the Phase 3 SYNCHRONY Outcomes study.
First patient dosed in Phase 3 SYNCHRONY Outcomes study of EFX in patients with compensated cirrhosis (F4) due to MASH.
Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027.
Phase 2b SYMMETRY study week 96 results expected to readout in February 2025.
Current cash, cash equivalents, and short- and long-term marketable securities will be sufficient to fund its Phase 3 SYNCHRONY Histology and Real-World studies through readout of their respective primary endpoints and Akero’s current operating plan into the second half of 2027.
Forward Guidance
Akero believes that its current cash, cash equivalents, and short- and long-term marketable securities will be sufficient to fund its Phase 3 SYNCHRONY Histology and Real-World studies through readout of their respective primary endpoints and Akero’s current operating plan into the second half of 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...